Derivation and external validation of risk algorithms for cerebrovascular (re)hospitalisation in patients with type 2 diabetes: Two cohorts study. (October 2018)

• Record Type: Journal Article
• Authors: Yu, Dahai; Cai, Yamei; Graffy, Jonathan; Holman, Daniel; Zhao, Zhanzheng; Simmons, David
• Is Part Of: Diabetes research and clinical practice. Volume 144(2018)
• Page Start: 74
• Page End: 81
• Publication Date: 2018-10
• Subjects: Cerebrovascular disease -- Diabetes population -- Risk prediction -- Primary care; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2018.08.006
• Languages: English
• ISSNs: 0168-8227

Abstract

Highlights: People with type 2 diabetes are in high risk of cerebrovascular diseases. No risk scores to predict risk of cerebrovascular (re)hospitalisation in diabetes. 2 Risk scores are derived to predict cerebrovascular (re)hospitalisation in diabetes. 2 Risk scores are externally validated in an independent cohort and performed well. 2 Risk scores can be used to inform clinical decision-making in primary care settings. Abstract: Aims: Cerebrovascular disease is one of more typical reasons for hospitalisation and re-hospitalisation in people with type 2 diabetes. We aimed to derive and externally validate two risk prediction algorithms for cerebrovascular hospitalisation and re-hospitalisation. Methods: Two independent cohorts were used to derive and externally validate the two risk scores. The development cohort comprises 4704 patients with type 2 diabetes registered in 18 general practices across Cambridgeshire. The validation cohort includes 1121 type 2 patients from a post-trial cohort data. Outcomes were cerebrovascular hospitalisation within two years and cerebrovascular re-hospitalisation within ninety days of the previous cerebrovascular hospitalisation. Logistic regression was applied to derive the two risk scores for cerebrovascular hospitalisation and re-hospitalisation from development cohort, which were externally validated in the validation cohort. Results: The incidence of cerebrovascular hospitalisation and re-hospitalisation was 3.76% and 1.46% in the development cohort, and 4.99% and 1.87% in the external validation cohort. Age, gender, body mass index, blood pressures, and lipid profiles were included in the final model. Model discrimination was similar in both cohorts, with all C-statistics > 0.70, and very good calibration of observed and predicted individual risks. Conclusion: Two new risk scores that quantify individual risks of cerebrovascular hospitalisation and re-hospitalisation have been well derived and externally validated. Both scores are on the basis of a few of clinical measurements that are commonly available for patients with type 2 diabetes in primary care settings and could work as tools to identify individuals at high risk of cerebrovascular hospitalisation and re-hospitalisation.